Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy

Area of Science:

• Uro-oncology
• Medical guidelines
• Nephrology

Background:

• The European Association of Urology (EAU) has updated its renal cancer treatment guidelines.
• Previous recommendations focused on a standard of care for patients with advanced renal cell carcinoma (RCC).

Discussion:

• The updated guidelines reflect advancements in systemic therapy for advanced renal cancer.
• Nivolumab (a PD-1 inhibitor) and cabozantinib (a tyrosine kinase inhibitor) are now recommended.
• These agents are indicated for patients progressing after one or more lines of vascular endothelial growth factor (VEGF) targeted therapy.

Key Insights:

• Nivolumab and cabozantinib represent a shift in treatment paradigms for refractory renal cancer.
• The updated EAU guidelines provide clear recommendations for sequencing therapies in advanced RCC.

Outlook:

• Further research will likely explore optimal sequencing and combinations of novel agents.
• These guideline changes aim to improve outcomes for patients with advanced renal cancer.